PL1625403T3 - Sposób przewidywania, diagnozowania i różnicowego diagnozowania choroby Alzheimera - Google Patents

Sposób przewidywania, diagnozowania i różnicowego diagnozowania choroby Alzheimera

Info

Publication number
PL1625403T3
PL1625403T3 PL04730881T PL04730881T PL1625403T3 PL 1625403 T3 PL1625403 T3 PL 1625403T3 PL 04730881 T PL04730881 T PL 04730881T PL 04730881 T PL04730881 T PL 04730881T PL 1625403 T3 PL1625403 T3 PL 1625403T3
Authority
PL
Poland
Prior art keywords
alzheimer
disease
diagnosis
prediction
differential diagnosis
Prior art date
Application number
PL04730881T
Other languages
English (en)
Inventor
Hugo Vanderstichele
Eugeen Vanmechelen
Kaj Blennow
Meyer Geert De
Vesna Kostanjevecki
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of PL1625403T3 publication Critical patent/PL1625403T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
PL04730881T 2003-05-22 2004-05-03 Sposób przewidywania, diagnozowania i różnicowego diagnozowania choroby Alzheimera PL1625403T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03447120A EP1480041A1 (en) 2003-05-22 2003-05-22 Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
US47762103P 2003-06-11 2003-06-11
PCT/EP2004/050684 WO2004104597A1 (en) 2003-05-22 2004-05-03 Method for the prediction, diagnosis and differential diagnosis of alzheimer's disease
EP04730881A EP1625403B1 (en) 2003-05-22 2004-05-03 Method for the prediction, diagnosis and differential diagnosis of alzheimer s disease

Publications (1)

Publication Number Publication Date
PL1625403T3 true PL1625403T3 (pl) 2008-10-31

Family

ID=33041166

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04730881T PL1625403T3 (pl) 2003-05-22 2004-05-03 Sposób przewidywania, diagnozowania i różnicowego diagnozowania choroby Alzheimera

Country Status (14)

Country Link
US (2) US20040265919A1 (pl)
EP (2) EP1480041A1 (pl)
JP (1) JP4769722B2 (pl)
AT (1) ATE386942T1 (pl)
AU (1) AU2004242203B2 (pl)
CA (1) CA2525781C (pl)
CY (1) CY1110252T1 (pl)
DE (1) DE602004011931T2 (pl)
DK (1) DK1625403T3 (pl)
ES (1) ES2301986T3 (pl)
PL (1) PL1625403T3 (pl)
PT (1) PT1625403E (pl)
SI (1) SI1625403T1 (pl)
WO (1) WO2004104597A1 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20080003625A1 (en) * 2004-07-19 2008-01-03 Younkin Steven G Predicting Alzheimer's Disease
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
CA2632822C (en) 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
ES2409058T3 (es) * 2006-04-13 2013-06-24 Eidia Co., Ltd. Método para someter a prueba la enfermedad de Alzheimer midiendo la tasa de degradación de beta-amiloide en sangre y reactivo de diagnóstico
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
CA2669848A1 (en) * 2006-11-17 2008-05-22 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Method of differentially diagnosing dementias
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
EP2586795B1 (en) 2007-10-05 2018-05-16 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN101977594B (zh) * 2008-02-01 2015-09-02 B.R.A.H.M.S有限公司 患有轻度认知障碍需要治疗的患者的鉴定方法以及这种患者的治疗
NZ590563A (en) 2008-07-21 2012-06-29 Probiodrug Ag Diagnostic antibody assay
EP2344881A4 (en) * 2008-09-26 2012-03-07 Univ Melbourne BIOMARKER FOR MORBUS ALZHEIMER
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20110091910A1 (en) * 2009-09-18 2011-04-21 Probiodrug Ag Novel assay
DK2510359T3 (en) * 2009-12-11 2015-12-07 Araclón Biotech S L METHODS AND REAGENTS FOR IMPROVED DETECTION OF AMYLOID-BETA PEPTIDES
DE102010014684A1 (de) * 2010-04-09 2011-10-13 Universität Duisburg-Essen Neue Ansätze zur Alzheimer-Diagnose
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
SI2885010T1 (sl) 2012-08-16 2020-07-31 Ipierian, Inc. Metode zdravljenja tauopatije
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
US20180252665A1 (en) * 2014-05-27 2018-09-06 Case Western Reserve University System and methods for the detection of biomarkers of neurodegenerative disorders
EP2950102A1 (en) * 2014-05-30 2015-12-02 Biocross, S.L. Method for the diagnosis of alzheimer s disease and mild cognitive impairment
EP3149486A1 (en) * 2014-05-30 2017-04-05 Biocross, S.L. Method for the diagnosis of alzheimer's disease and mild cognitive impairment
CN113884683A (zh) * 2020-07-30 2022-01-04 山东京济生物工程有限公司 一种快速检测Aβ42的双抗体夹心ELISA试剂盒
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
US20240159777A1 (en) * 2021-03-16 2024-05-16 Neurovision Imaging, Inc. Biofluid-Based Methods for Diagnosing Alzheimer’s Disease-Associated Conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1994017197A1 (fr) * 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
US6632526B1 (en) * 1997-10-14 2003-10-14 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20020182660A1 (en) * 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
ES2228697T3 (es) * 2001-06-12 2005-04-16 Wiltfang, Jens Anticuerpo monoclonal, mab 1e8, que es especifico para los dos primeros aminoacidos de peptidos beta-amiloides y su utilizacion en la deteccion de peptidos beta-amiloides y/o sapp alfa.
DE60224200T2 (de) * 2001-08-17 2008-07-10 Eli Lilly And Co., Indianapolis Assayverfahren für alzheimer-krankheit

Also Published As

Publication number Publication date
ATE386942T1 (de) 2008-03-15
ES2301986T3 (es) 2008-07-01
EP1625403A1 (en) 2006-02-15
PT1625403E (pt) 2008-05-28
WO2004104597A1 (en) 2004-12-02
JP2007522434A (ja) 2007-08-09
US20040265919A1 (en) 2004-12-30
DK1625403T3 (da) 2008-06-09
CY1110252T1 (el) 2015-01-14
EP1625403B1 (en) 2008-02-20
DE602004011931T2 (de) 2009-09-10
CA2525781A1 (en) 2004-12-02
AU2004242203B2 (en) 2008-12-11
DE602004011931D1 (de) 2008-04-03
JP4769722B2 (ja) 2011-09-07
AU2004242203A1 (en) 2004-12-02
US20080057593A1 (en) 2008-03-06
CA2525781C (en) 2013-08-13
EP1480041A1 (en) 2004-11-24
SI1625403T1 (sl) 2008-08-31

Similar Documents

Publication Publication Date Title
PL1625403T3 (pl) Sposób przewidywania, diagnozowania i różnicowego diagnozowania choroby Alzheimera
WO2005061545A3 (en) Nogoa antibodies for the treatment of alzheimer disease
AU2002257162A1 (en) Humanized antibodies
AU2002258808A1 (en) Humanized antibodies
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2005047484A3 (en) Biomarkers for alzheimer's disease
Vodanovich On the possible benefits of boredom: A neglected area in personality research.
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
WO2004043226A3 (en) Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease
WO2005027733A3 (en) Biological markers for diagnosing multiple sclerosis
AU2003217652A1 (en) Methods for continuous performance testing
AU2002238766A1 (en) Diagnostic screens for alzheimer's disease
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
ZA200603178B (en) Quick test for the diagnosis of Alzheimer's disease
WO2006067792A3 (en) Aldolase autoantigens useful in diagnosis and treatment of alzheimer's disease
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
AU2002366555A1 (en) Diagnostic for early stage alzheimer's disease
EP1693671A4 (en) METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE
DE60127901D1 (de) TCF-1 Nukleotidsequenzvariation
WO2006032021A3 (en) Identification of gene associated with reading disability and uses therefor
AU2003235113A8 (en) Method of measuring neprilysin activity
WO2005001483A3 (en) Methods for diagnisis and differential diagnosis of dementia disorders
AU2001273675A1 (en) Methods and assays for diagnosing alzheimer's disease
Barbosa (Cognitive Development)=(Biology+ Social Context): Is the Whole the Sum of Parts?